Tim's Co., Ltd.
Basic information
- Head office
- 11th Floor, Keio Fuchu 1-chome Building, 1-9 Fuchucho, Fuchu City, Tokyo
- Chief executive
- Takuro Wakabayashi
- Capital
- 1,137,000,000 (11 100 million)
- Employees (non-consolidated)
- 18 people
- Employees (consolidated)
- 18 people
- Start date
- 2005-02-17
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
| 国立大学法人九州大学 | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| バイオジェン社 | ||||||||
|
|
||||||||
| IR Robotics社 | ||||||||
| JIXING | ||||||||
| Pathology Associates | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| CORXEL社 |
Network
History
Between 2005 and 2011, the pharmacological efficacy tests of SMTP confirmed thrombolytic promotion, anti-inflammatory, and cerebral infarction improvement effects.
Confirmed thrombolytic promotion, anti-inflammatory, and cerebral infarction improvement effects in SMTP pharmacological efficacy tests (2005-2011).
Founded in February 2005 with the purpose of commercializing the medicinal seed discovered by Professor Keiji Renmi of the Fermentation Laboratory at Tokyo University of Agriculture and Technology.
Company establishment
Invested in our company in 2007.
In November 2011, non-clinical trials of TMS-007 were initiated.
Started non-clinical trials of TMS-007.
In October 2014, Phase I clinical trials of TMS-007 were started.
Started Phase I clinical trial of TMS-007.
In October 2015, Phase I clinical trials of TMS-007 were completed.
Completed Phase I clinical trial of TMS-007.
In February 2018, Phase II clinical trials of TMS-007 were started.
Started Phase II clinical trial of TMS-007.
In June 2018, an option agreement was signed to transfer the lead compound TMS-007 to BioGen for a total of $357 million.
Entered into an option agreement to license TMS-007 to Biogen.
© 2021 TMS Co., Ltd.
In May 2021, BioGen exercised its option rights for TMS-007.
Biogen exercised its option rights for TMS-007.
In August 2021, the first Phase II trial of TMS-007 was completed.
Completed the interim Phase II trial of TMS-007.
In November 2022, the company was listed on the Tokyo Stock Exchange Growth Market (ticker: 4891).
Listed on the Tokyo Stock Exchange Growth Market (ticker: 4891).
In January 2024, BioGen transferred the rights to TMS-007 to JIXING.
In January 2024, a strategic partnership agreement with JIXING was signed, securing development and sales rights for TMS-007 and JX09 in Japan.
Biogen transferred rights to TMS-007 to JIXING.
Entered into a strategic partnership agreement with JIXING and obtained development and sales rights for TMS-007 and JX09 in Japan.
News
There is no news.
Public records
National Tax Agency basic information5013401006469
- Trade name
- 株式会社ティムス
- Trade name (kana)
- ティムス
- Name in English
- Corporation type
- 301
- Address
- 〒183-0055 東京都府中市府中町１丁目９番地
- Postal code
- 1830055
- Prefecture code
- 13
- City code
- 206
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2022-02-17
- Change date
- 2022-02-14
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 2007360
METI gBizINFO5013401006469
- Corporate number
- 5013401006469
- Trade name
- 株式会社ティムス
- Trade name (kana)
- ティムス
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都府中市府中町１丁目９番地
- Postal code
- 1830055
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 府中市
- City code
- 206
- Street address
- 府中町１丁目９番地
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 0
- Status
- Representative
- 代表取締役社長 若林 拓朗
- Capital
- 1137611000
- Employees
- 18
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2022-02-17
- Key information
- 5013401006469